AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Clinical Trials

Study finds first evidence that PrEP can reduce HIV risk among people who inject drugs

CDC Logo

Daily HIV medications now proven to prevent HIV among all groups at high risk A daily dose of a medication used to treat HIV infection reduced the risk of HIV acquisition among people who inject drugs by 49 percent. Those who took the medication most consistently had even higher levels of protection, according to a…

Statement: NIH Discontinues Immunizations in HIV Vaccine Study

NIAID

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board (DSMB) found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor…

Daily-use HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study

blog.aids.gov

According to findings of a major HIV prevention trial presented Monday, March 4, 2013 at the 20th Conference on Retroviruses and Opportunistic Infections (CROI), study participants who received daily oral pre-exposure prophylaxis (PrEP) did not experience any protection against HIV compared to those in the placebo arm, likely because very few were taking the study…

NIAID Advances Efforts to Restructure Clinical Trials Networks with Funding Announcements

NIAID wordle

Over the past year and a half, many of you followed the AIDS.gov blog post series Future Directions for NIAID HIV Research by Dr. Carl Dieffenbach, Director of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH. Last week, NIAID advanced those efforts by issuing several requests for applications (RFAs)…

Community Engagement in NIAID’s HIV/AIDS Clinical Trials Networks

Future Directions for NIAID HIV Research: Consider and Comment

Since early in the HIV/AIDS epidemic, the National Institute of Allergy and Infectious Diseases (NIAID) has involved community representatives and advocates in the research process.   The nature and scope of the community’s involvement have grown over the years, but the rationale behind these efforts remains the same:  the people who might benefit from the research…

The Future of the NIAID Clinical Trial Units

NIAID

As the National Institute of Allergy and Infectious Diseases (NIAID) moves forward to restructure its HIV/AIDS Clinical Trials Networks and include a new network focused on infectious diseases other than AIDS, the Clinical Trial Units (CTUs) will continue to play a critical role in establishing, developing, and implementing the networks’ scientific research agendas. Additionally, we…

HIV Vaccine Awareness Day, 2011

blog.aids.gov

Co-authored by Margaret (Peggy) Johnston, Ph.D., Senior Scientific Consultant, NIAID.

HIV Vaccine Awareness Day provides an opportunity to acknowledge the more than 35,000 individuals who have volunteered for preventive HIV vaccine trials over the past 25 years. Without their participation, the modest success that we have achieved

Research Update: Treating HIV-infected People with Antiretrovirals Protects Partners from Infection: CDC Statement

NIHWordle

Yesterday, we blogged that NIH released findings from an important large-scale clinical study that found that men and women living with HIV who took oral antiretroviral medicines when their immune systems were relatively healthy, were able to reduce the risk of transmitting the virus to their sexual partners. We also heard from the CDC Director…